Shares of Synergy Pharmaceuticals, Inc. (SGYP) are up 2.24% to $59.35 in Thursday’s pre-market trading after the company announced positive top-line results from its second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses in patients with chronic Idiopathic constipation. “We are thrilled with the positive […]
View the full post at: Morning Buzz: Synergy (SGYP), Ascendis Pharma (ASND), Gevo (GEVO), 3D Systems (DDD), Baidu, (BIDU)